HOME >> BIOLOGY >> NEWS
Researchers Discover Why Some Athletes' Performances Fail To Improve On A Live-High, Train-Low Regimen

DALLAS - December 30, 1998 - Exercise physiology researchers at UT Southwestern Medical Center at Dallas have learned why certain athletes don't respond to the internationally accepted "live-high, train-low" paradigm. The regimen - essentially living in the thin mountain air while training at lower altitudes to increase athletic endurance - is not effective in athletes unable to produce a sustained amount of a crucial red blood cell-increasing hormone.

"We've figured out some of the differences between the athletes who do and don't respond to altitude training. So now we hope to extend this research and predict who will and who won't respond with a screening test," said Dr. Benjamin Levine, associate professor of internal medicine at UT Southwestern and director of the Institute for Exercise and Environmental Medicine (IEEM) - a collaboration between UT Southwestern and Presbyterian Hospital of Dallas.

Exercise physiologists have known for years that, in most cases, the body responds to high altitude by producing more red blood cells to boost oxygen levels. That formed the basis of Levine's original 1997 study performed in collaboration with Dr. James Stray-Gundersen, a former assistant professor of surgery at UT Southwestern who now works with Norway's Olympic ski team.

The new study was published in the October issue of Journal of Applied Physiology. Levine's team, including Stray-Gundersen and UT Southwestern postdoctoral fellow Dr. Robert Chapman, looked at data from previous altitude studies, specifically, erythropoietin (EPO) concentrations in 39 collegiate runners living at high altitudes. Those who responded to the live-high, train-low regimen showed a significantly larger increase in EPO concentration than the nonresponders. The researchers theorized that this increased EPO concentration allows the body to make more red cells while at high altitudes and that, in turn, increases maximal oxygen uptake, which was shown through higher scores in
'"/>

Contact: Jennifer Haigh-Manley
jhaigh@mednet.swmed.edu
214-648-3404
UT Southwestern Medical Center
30-Dec-1998


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary commercial focus on ... has been granted a Type C meeting with the ... meeting will be held in February 2015.  During this ...
(Date:12/15/2014)... DIEGO , Dec. 15, 2014 ... three-dimensional biology company focused on delivering breakthrough 3D ... the industry and collaborators of its exVive3D TM ... made widely available in full commercial release on ... the field, resulting in several awards for innovation. ...
(Date:12/13/2014)... and Virgin Unite Canada, the non-profit foundation of the Virgin ... Canadian entrepreneurs tackling social and environmental challenges. Today, Sir ... Centre to announce the new partnership, which includes the development ... $1 million in seed capital provided by Virgin Unite Canada ... Foundation, founded by Alison Lawton . ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3MaRS and Virgin Unite partner to invest in business as a force for good 2MaRS and Virgin Unite partner to invest in business as a force for good 3
Cached News: